Skip to main content
. 2023 Mar 8;159(4):403–410. doi: 10.1001/jamadermatol.2022.6687

Figure 1. Flowchart of the Study.

Figure 1.

Flowchart of the study, showing the number of patients who achieved a complete or almost complete hair regrowth (Severity of Alopecia Tool [SALT] score <10) according to treatment groups: (1) placebo alone for 12 months (n = 1); (2) methotrexate alone (for 6 to 12 months) (n = 35), corresponding to patients who received methotrexate from baseline to month 12 (n = 3), patients who received methotrexate from baseline to month 6 and were rerandomized to receive methotrexate + a placebo of prednisone for 6 months (month 6 to month 12) (n = 16), and patients who received placebo from baseline to month 6 and were rerandomized to receive methotrexate plus a placebo of prednisone for 6 months (month 6 to month 12) (n = 16); and (3) methotrexate plus prednisone (n = 35), corresponding to patients who received methotrexate from baseline to month 6 and were rerandomized at month 6 to receive methotrexate plus prednisone from month 6 to month 12 (n = 16) (these patients thus received methotrexate for 12 months and prednisone for 6 months) and patients who received a placebo of methotrexate from baseline to month 6 and were rerandomized at month 6 to receive methotrexate plus prednisone from month 6 to month 12 (n = 19) (these patients thus received methotrexate for 6 months and prednisone for 6 months).